| Symposium Participants |
|
v | |
| Foreword |
|
xvii | |
|
|
|
|
Normal and Neoplastic Stem Cells |
|
|
1 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Targeting the Epithelial-to-Mesenchymal Transition: The Case for Differentiation-Based Therapy |
|
|
11 | (10) |
|
|
|
|
|
Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations |
|
|
21 | (10) |
|
|
|
|
|
|
|
Cell of Origin and Cancer Stem Cells in Tumor Suppressor Mouse Models of Glioblastoma |
|
|
31 | (6) |
|
Sheila R. Alcantara Llaguno |
|
|
|
|
|
|
|
|
|
|
|
37 | (4) |
|
|
|
Alterations in Three-Dimensional Organization of the Cancer Genome and Epigenome |
|
|
41 | (12) |
|
|
|
|
|
|
|
Composition and Function of Mammalian SW1/SNF Chromatin Remodeling Complexes in Human Disease |
|
|
53 | (8) |
|
|
|
|
|
The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia |
|
|
61 | (6) |
|
|
|
|
|
|
|
|
Reexamining How Cancer Cells Exploit the Body's Metabolic Resources |
|
|
67 | (6) |
|
|
|
|
|
Autophagy, Metabolism, and Cancer |
|
|
73 | (6) |
|
|
|
|
|
A Time for MYC: Metabolism and Therapy |
|
|
79 | (6) |
|
|
|
Beyond the Oncogene Revolution: Four New Ways to Combat Cancer |
|
|
85 | (8) |
|
|
|
|
|
|
|
Lipid Synthesis Is a Metabolic Liability of Non-Small Cell Lung Cancer |
|
|
93 | (12) |
|
|
|
|
|
Targets, Vaccines, and Therapeutics |
|
|
|
Cancer Immunogenomics: Computational Neoantigen Identification and Vaccine Design |
|
|
105 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Targeting HIF2 in Clear Cell Renal Cell Carcinoma |
|
|
113 | (10) |
|
|
|
|
|
BET Bromodomain Proteins as Cancer Therapeutic Targets |
|
|
123 | (8) |
|
|
|
|
|
To Prime, or Not to Prime: That Is the Question |
|
|
131 | (10) |
|
|
|
|
|
Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer |
|
|
141 | (10) |
|
|
|
|
|
|
|
|
|
Microenvironment and Metastasis |
|
|
|
Tumor-Stroma Interactions in Bone Metastasis: Molecular Mechanisms and Therapeutic Implications |
|
|
151 | (12) |
|
|
|
|
|
|
|
Cancer, Oxidative Stress, and Metastasis |
|
|
163 | (14) |
|
|
|
|
|
|
|
RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers |
|
|
177 | (12) |
|
|
|
|
|
Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and Metastasis |
|
|
189 | (18) |
|
|
|
|
|
|
|
|
Pathways Involved in Formation of Mammary Organoid Architecture Have Keys to Understanding Drug Resistance and to Discovery of Druggable Targets |
|
|
207 | (12) |
|
|
|
|
|
Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities |
|
|
219 | (8) |
|
|
|
Modeling Breast Cancer Intertumor and Intratumour Heterogeneity Using Xenografts |
|
|
227 | (4) |
|
|
|
|
|
|
|
Challenges and Opportunities in Modeling Pancreatic Cancer |
|
|
231 | (6) |
|
|
|
|
|
Cancer Genomics and Tumor Heterogeneity |
|
|
|
Functional Genomic Characterization of Cancer Genomes |
|
|
237 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations? |
|
|
247 | (10) |
|
|
|
|
|
|
|
A Pipeline for Drug Target Identification and Validation |
|
|
257 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity |
|
|
269 | (6) |
|
|
|
|
|
|
|
|
|
|
|
Discovery of Double-Stranded Genomic DNA in Circulating Exosomes |
|
|
275 | (6) |
|
|
|
|
|
|
|
|
|
|
281 | (8) |
|
|
|
|
|
|
|
289 | (8) |
|
|
|
291 | (6) |
|
Conversations at the Symposium |
|
|
297 | (66) |
|
|
|
299 | (2) |
|
|
|
301 | (3) |
|
|
|
304 | (2) |
|
|
|
306 | (3) |
|
|
|
309 | (2) |
|
|
|
311 | (3) |
|
|
|
314 | (3) |
|
|
|
317 | (3) |
|
|
|
320 | (3) |
|
Guillermina (Gigi) Lozano |
|
|
323 | (3) |
|
|
|
326 | (2) |
|
|
|
328 | (3) |
|
|
|
331 | (3) |
|
|
|
334 | (2) |
|
|
|
336 | (2) |
|
|
|
338 | (3) |
|
|
|
341 | (3) |
|
|
|
344 | (3) |
|
|
|
347 | (4) |
|
|
|
351 | (3) |
|
|
|
354 | (3) |
|
|
|
357 | (3) |
|
|
|
360 | (3) |
| Author Index |
|
363 | (2) |
| Subject Index |
|
365 | |
